By Karen Roman ReAlta Life Sciences said it is presenting new data from its hypoxic ischemic encephalopathy (HIE) program at the Pediatric Academic Societies Annual Meeting, taking place in Honolulu, Hawaii, from April 24-28, 2025. The findings confirm elevated inflammatory...

By Karen Roman March Biosciences said it started Phase 2 trial for MB-105, its CAR-T therapy for patients with relapsed or refractory CD5+ T-cell lymphoma. The test will take place at leading cancer centers across the country, with the first...

By Karen Roman Ascentage Pharma Group Internat (Nasdaq: AAPG) said two of its proprietary drugs have been included in the 2025 Chinese Society of Clinical Oncology (CSCO) Guidelines. The added drugs are lisaftoclax and olverembatinib; the former used to diagnose...

By Karen Roman Nano-X Imaging Ltd. (Nasdaq: NNOX) said its multi-source digital imaging system, Nanox.ARC X, received FDA 510(k) clearance for general use. The Nanox.ARC X has a simplified “plug and play” one-day installation feature and allows remote software upgrades,...

By Karen Roman Biopharmaceutical company ReAlta Life Sciences said it designated immunologist Laurie Glimcher, M.D., to its Board of Directors. Dr. Glimcher is renowned for her 35 years of work in cancer research, and she is the Richard and Susan...

By Karen Roman Vivani Medical, Inc. (Nasdaq: VANI) announced positive data for NPM-139, its subdermal semaglutide implant for chronic weight management, with expected once or twice-yearly dosing. The results support the company’s NanoPortal implant for delivery of therapeutic molecules for...

By Karen Roman Private equity company Jeito Capital said it is co-leading an oversubscribed €77.7 million (USD 84.8 million) Series A financing round in Augustine Therapeutics. The founding will support Phase 2 of AGT-100216, Augustine’s main candidate for Charcot-Marie-Tooth disease...

By Daniella Parra Taiho Pharmaceutical said it will acquire Araris Biotech, a leader in antibody drug conjugates (ADCs), for an initial $400 million, with potential additional milestone payments of up to $740 million. Araris’ AraLinQ platform enhances ADC drug design,...

By Karen Roman Vivani Medical, Inc. (Nasdaq: VANI) announced it finished the placement of NPM-115, its GLP-1 (exenatide) implant, in the first-in-human clinical trial of its kind. The company also said it achieved full enrollment for this study, which targets...

By Karen Roman Vivani Medical, Inc. (Nasdaq: VANI) said it expects to spin off Cortigent, Inc., its brain implant devices division, as an independent publicly-traded company. Vivani aims to create two companies focused on driving long term value creation in...